The FDA Center for Drug Evaluation and Research has accepted a letter of intent for the first biomarker for idiopathic ...
The BMP8A Fibrosis Score (BFS) offers improved accuracy over existing noninvasive scoring systems for identifying advanced liver fibrosis in MASH patients. BFS eliminates grey-zone results, providing ...
Novel non-invasive liver disease assessments (NILDAs) are effective alternatives to liver biopsy for the treatment of liver ...
Background: The Prognostic Lung Fibrosis Consortium (PROLIFIC) was formed to develop well-qualified assays suitable for use as prognostic biomarkers within the context of clinical trials for Idiopathic ...
A new study links telomere length genetics to IPF risk, showing how rare variants and polygenic scores may guide future screening and precision care.
Novel non-invasive liver disease assessments (NILDAs) can effectively replace liver biopsy for assessing liver fibrosis in ...
Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD); (OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to fibroinflammatory diseases, today announced ...
Adverse pregnancy outcomes in women with MASLD are driven by underlying metabolic comorbidities, not MASLD itself or fibrosis severity. Maternal and fetal outcomes are not affected by metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results